|
Based on your IP address, your paper is being delivered by:
|
 |
 |
 |
 |
 |
New York, USA
Processing request.
|
Illinois, USA
Processing request.
|
Brussels, Belgium
Processing request.
|
Seoul, Korea
Processing request.
|
California, USA
Processing request.
|
If you have any problems downloading this paper,
please click on another Download Location above, or
File name: SSRN-id1824267. ; Size: 178K
|
|
Impact of Profitability, R&D Intensity, and Cash Flow on R&D Expenditure in Pharmaceutical Companies
Destrina Grace Simanjuntak
Dexa Laboratories of Biomolecular Sciences, Dexa Medica Group
Raymond R. Tjandrawinata
Department of Business Development and Dexa Laboratories of Biomolecular Sciences, PT Dexa Medica
April 29, 2011
Abstract:
This paper empirically examines the influence of the determinants of R&D expenditure, such as firm’s lagged profitability, R&D intensity, and cash flow on R&D expenditure of the pharmaceutical companies. All of them have an important roles in determining the steps of the corporate strategy to investing in R&D activities. The data used in this study was gathered from six large pharmaceutical companies in the U.S., in the period of 2003 to 2010. The result shows that firm’s lag profitability, R&D intensity, and cash flow have the positive influence and affect significantly the firms amount R&D expenditure in the pharmaceutical companies. Thus, enhancement in the firm’s one-year lagged profitability, R&D intensity, and cash flow can increase firm’s amount of R&D expenditure.
Number of Pages in PDF File: 13
Keywords: Research and Development Expenditure, Profitability, R&D Intensity, Cash Flow
JEL Classification: I11, L21, L65, O30
working papers series
Download This Paper
Date posted: May 5, 2011
Suggested CitationSimanjuntak, Destrina Grace and Tjandrawinata, Raymond R., Impact of Profitability, R&D Intensity, and Cash Flow on R&D Expenditure in Pharmaceutical Companies (April 29, 2011). Available at SSRN: http://ssrn.com/abstract=1824267 or http://dx.doi.org/10.2139/ssrn.1824267
|
| Feedback to SSRN (Beta) |
|
|
People who downloaded this paper also downloaded:
1.
Deriving the Free Cash Flow (FCF) for Firm Valuation - Why We Should Include the Change in Non-Operational Working Capital in the Net Working Capital Calculation When Deriving the FCF
By
Robert Stockfis
2.
Brand Capital and Firm Value
By
Frederico Belo,
Xiaoji Lin, ...
3.
Cyclicality, Performance Measurement, and Cash Flow Liquidity in Private Equity
By
David Robinson
and
Berk Sensoy
4.
Optimal Capital Structure
By
Jules Van Binsbergen,
John Graham, ...
5.
An Asset Pricing Approach to Liquidity Effects in Corporate Bond Markets
By
Dion Bongaerts,
Frank De Jong, ...
6.
Analysis of the Role of Working Capital and Cash Flow in Management of Limited Liability Companies
By
Marlena Grabowska
7.
Endogeneity in Empirical Corporate Finance
By
Michael Roberts
and
Toni Whited
8.
Firm Profitability, Inventory Volatility, and Capital Structure
By
John Birge
and
Xiaodong Xu
9.
Intellectual Capital Evaluation: Relationship between Knowledge Management Implementation and Company’s Performance
By
Elena Shakina
and
Anna Bykova
10.
Life-Cycle Theory and Free Cash Flow Hypothesis: Evidence from Dividend Policy in Thailand
By
Yordying Thanatawee
|
|
|
|
